Long-acting glucagon-like peptide-2 analogs, methods of making and uses thereof

By modifying and synthesizing GLP-2, a GLP-2 analogue with a longer half-life and higher stability was designed, solving the problem of the short half-life of existing GLP-2 and realizing better potential for clinical application.

CN122404530APending Publication Date: 2026-07-17SUZHOU QINGRUI BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SUZHOU QINGRUI BIOTECHNOLOGY CO LTD
Filing Date
2026-01-16
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

The short half-life of existing GLP-2 leads to the need for frequent injections, which affects patient compliance. Furthermore, existing analogues have low in vitro efficacy and require high doses to be effective.

Method used

By modifying the structure of GLP-2, a GLP-2 analogue was designed to increase its chemical stability and half-life while retaining its biological activity. It was synthesized using the standard fluorenylmethoxycarbonyl solid-phase synthesis technique.

Benefits of technology

This study achieved an extended half-life, improved stability, and superior bioactivity compared to apraglutide, demonstrating promising clinical application prospects for GLP-2 analogs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122404530A_ABST
    Figure CN122404530A_ABST
Patent Text Reader

Abstract

本发明属于医药领域，具体涉及一种胰高血糖素样肽‑2(GLP‑2)类似物及其制备方法和在预防和治疗例如胃肠相关病症以及减轻化学疗法和放射性疗法的副作用中的用途。本发明针对目前现有技术存在的天然的GLP‑2半衰期短、不具有临床药物价值这一技术问题，提供一类GLP‑2类似物，与野生GLP‑2相比，所述GLP‑2类似物具有更稳定的化学特性，更长的半衰期，同时仍然保留具有类似于GLP‑2的生物活性，且所述GLP‑2类似物的效果显著优于Apraglutide，具有良好的临床应用前景。
Need to check novelty before this filing date? Find Prior Art